180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has published a preclinical study report on the effects of cannabigerol (“CBG”) derivatives on pain, inflammation and obesity. The report  was published in the “Molecules” journal. ATNF has worked closely with … Continue reading InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Preclinical Report on the CBG Impact on Pain, Inflammation, Obesity